Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2015-04-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事马清钧2014年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Beijing Shuanglu Pharmaceutical Co., Ltd. for the year 2014. It includes comprehensive information about the director's attendance at meetings, opinions on profit distribution, internal control evaluations, audit firm reappointment, related party transactions, short-term investments, guarantees, entrusted loans, and protection of minority shareholders' rights. The content is substantive and covers governance, financial oversight, and operational matters for the full fiscal year 2014. It is not a brief announcement or a certification letter but a full report on the director's duties and opinions for the year. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document is not an Annual Report (10-K) or Audit Report (AR) because it focuses on the independent director's report rather than full financial statements or audit opinions alone. Therefore, the best classification is MANG with high confidence.
2015-04-27 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Audit Report) for Beijing SL Pharmaceutical Co., Ltd., dated April 26, 2015, covering the internal control evaluation as of December 31, 2014. It is issued by a certified public accounting firm and includes detailed descriptions of the internal control environment, risk assessment, control activities, information and communication, and internal supervision. The document contains an auditor's opinion on the effectiveness of internal controls related to financial reporting, as well as the company's self-evaluation report on internal controls. It is a standalone audit-related report focusing on internal control effectiveness and does not constitute a full annual report or interim financial report. It is not a regulatory announcement or a brief notice but a detailed audit report on internal controls. Therefore, it fits the category of Audit Report / Information (AR). The document length (13,877 characters) supports it being a full report rather than a brief announcement. FY 2014
2015-04-27 Chinese
2014年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2014 年年度报告摘要" which translates to "2014 Annual Report Summary". It contains detailed financial data for the year 2014, including revenue, net profit, earnings per share, and asset information. It also includes management discussion and analysis of the company's operations, business segments, and accounting policy changes. The document is about 7800 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or a brief summary. The content aligns with the characteristics of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year 2014. Therefore, the appropriate classification is Annual Report (10-K). FY 2014
2015-04-27 Chinese
监事会对公司2014年内部控制评价报告的意见
Audit Report / Information Classification · 95% confidence The document is an opinion statement from the Supervisory Board regarding the company's 2014 internal control evaluation report. It references regulatory guidelines and confirms the effectiveness of internal controls for the year 2014. The document does not contain the full internal control report itself but rather the Supervisory Board's review and opinion on that report. It is a standalone audit-related statement focusing on internal controls, which aligns with the category of Audit Report / Information (AR). The document length is short but contains substantive content beyond a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2014
2015-04-27 Chinese
独立董事候选人声明（苏志国）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or report summaries. The content is focused on governance and compliance related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to announcements about board members and their qualifications rather than financial or regulatory filings.
2015-04-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing SL Pharmaceutical Co., Ltd. regarding a change in accounting policies. It details the reasons for the change, the specific accounting standards affected, the impact on financial statement line items, and includes opinions from the board of directors, independent directors, and the supervisory board. The document is relatively short (3406 characters) and does not contain full financial statements or comprehensive financial data. It is primarily an announcement of a change in accounting policy rather than a full financial report or audit report. It does not fit the definitions of Annual Report, Interim Report, Audit Report, or Management Report. It is not a regulatory certification or officer attestation. The content is focused on accounting policy change disclosure, which is typically classified under Regulatory Filings (RNS) as it is a regulatory announcement that does not constitute a full report or detailed financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.